Overview
- 10 public-safe observations are available for this inspection.
- 5 structured CFR citations are represented.
- 2 investigators are tied to this Form 483.
Inspectional observations
Each observation cites the regulation FDA found the firm out of compliance with.
6 Dec 2023
21 CFR 111.113(b)(1)
Quality control - dietary supplement; adulteration
Cited by Maressa L Mills, Alissa C Rice
6 Dec 2023
21 CFR 111.113(b)(1)
Quality control - dietary supplement; adulteration
Cited by Maressa L Mills, Alissa C Rice
6 Dec 2023
21 CFR 111.70(c)(1)
In-process identity, purity, strength, composition
Cited by Maressa L Mills, Alissa C Rice
Inspected site
CLCE-Bio LLCMemphis, United States
Inspection team
Cited regulations
CFR citations associated with this Form 483.
| Citation | What it covers | Cited |
|---|---|---|
| 21 CFR 111.113(b)(1) | Cited across public-safe Form 483 observations | 2x |
| 21 CFR 111.255(b) | Cited across public-safe Form 483 observations | 2x |
| 21 CFR 111.70(c)(1) | Cited across public-safe Form 483 observations | 2x |
| 21 CFR 111.70(d) | Cited across public-safe Form 483 observations | 2x |
| 21 CFR 111.70(e) | Cited across public-safe Form 483 observations | 2x |
Full 483 report
Get the verbatim text of all 10 observations
The full inspection record, as Atlas holds it, so your team sees exactly what was cited and how it was answered.
- The site's full inspection history around this Form 483
- Whether these citations escalated to a warning letter
- The investigators involved and the citations they repeat elsewhere